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Abstract
Development of effective malaria vaccines is hampered by the problem of producing correctly folded Plasmodium proteins
for use as vaccine components. We have investigated the use of a novel ciliate expression system, Tetrahymena thermophila,
as a P. falciparum vaccine antigen platform. A synthetic vaccine antigen composed of N-terminal and C-terminal regions of
merozoite surface protein-1 (MSP-1) was expressed in Tetrahymena thermophila. The recombinant antigen was secreted into
the culture medium and purified by monoclonal antibody (mAb) affinity chromatography. The vaccine was immunogenic in
MF1 mice, eliciting high antibody titers against both N- and C-terminal components. Sera from immunized animals reacted
strongly with P. falciparum parasites from three antigenically different strains by immunofluorescence assays, confirming
that the antibodies produced are able to recognize parasite antigens in their native form. Epitope mapping of serum
reactivity with a peptide library derived from all three MSP-1 Block 2 serotypes confirmed that the MSP-1 Block 2 hybrid
component of the vaccine had effectively targeted all three serotypes of this polymorphic region of MSP-1. This study has
successfully demonstrated the use of Tetrahymena thermophila as a recombinant protein expression platform for the
production of malaria vaccine antigens.
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Introduction
Malaria continues to be a major public health challenge,
particularly among children and pregnant women in sub-Saharan
Africa [1]. Prompt medical intervention is unavailable in many
malaria-endemic regions due to limitations in healthcare infra-
structure, organization and resources. In light of the continuing
emergence of drug-resistant strains of Plasmodium falciparum, there is
a pressing need for effective vaccines against malaria [2].
There are a limited number of candidate malaria vaccine
antigens in various stages of development, from early proof-of-
concept studies to late-phase clinical trials [3,4]. An extensive
array of expression platforms have been used to generate vaccine
antigens against malaria, including synthetic peptides, viral
delivery systems, bacteria, transgenic plants or animals, insect
cells, mammalian cell lines and yeast [5–9]. The production of
Plasmodium proteins for use in subunit vaccines using heterologous
expression systems presents a number of challenges, since efficient
expression of correctly folded proteins may be precluded by the
inherent characteristics of many P. falciparum genes and their
products, such as repetitive sequence content, large open reading
frames, complex disulfide bonding patterns and the high AT
content of P. falciparum DNA [10,11]. In this study we investigated
the use of a promising protozoan protein expression system similar
to Plasmodium falciparum parasite’s own biosynthetic machinery.
Tetrahymena thermophila is a ciliated protozoan belonging to the
eukaryotic clade alveolata that also includes Plasmodium spp. [12]. It
shares some inherent characteristics with P. falciparum, such as
similar codon usage bias and the production of a number of large
and structurally complex proteins [11,12]. As a biotechnological
expression system, T. thermophila cells grow rapidly to high densities
in simple, inexpensive media. The fermentation process uses
conventional bioreactor equipment typically used for E. coli or
yeast systems, and it is readily up-scalable to large volumes suitable
for bioprocess production [13,14]. Finally, as there is no evidence
that T. thermophila harbours any pathogenic viruses or pyrogens
[15], proteins expressed in this system should be biologically safe
and free from human pathogens.
It has previously been demonstrated that T. thermophila can
express genes from heterologous species. Initially, a surface antigen
of the fish ectoparasite Ichthyophthirius multifiliis was expressed on
the surface of the ciliate [16]. Subsequently, the full-length
expression of the GPI-anchored circumsporozoite protein of
Plasmodium falciparum and surface expression of the C-terminal
19 kDa region of merozoite surface protein 1 (MSP-1) have been
achieved [17,18]. More recently, human enzymes have been
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e87198
expressed and purified from T. thermophila [19]. However, to date
successful production and immunogenicity testing of a soluble
Plasmodium protein expressed in Tetrahymena has not been
described.
MSP-1 is the most abundant surface protein of the invasive
merozoite stage of the P. falciparum life cycle, making up 40% of the
GPI-anchored surface protein coat [20,21]. The molecule can be
divided into 17 blocks based on sequence diversity from primary
sequence alignments from different strains [22]. The N-terminal
Block 2 region of MSP-1 is by far the most polymorphic region of
the molecule, with hundreds of known variant sequences from
globally diverse parasite isolates [23,24]. MSP-1 Block 2 represents
a promising target for malaria vaccine development, since several
seroepidemiological studies have shown that individuals with
antibodies to MSP-1 Block 2 have reduced risk of subsequent
clinical malaria episodes [25–29]. Antibodies to MSP-1 Block 2
have also been shown to inhibit parasite growth in antibody-
dependent cellular inhibition (ADCI) assays [30]. The allelic
diversity of MSP-1 Block 2 gives rise to the possibility that variant-
specific immune responses may be elicited that would fail to
provide protection against all parasite genotypes of a given
population. To overcome this problem, a synthetic hybrid antigen
that covers all known sequence diversity of the MSP-1 Block 2
region was designed and has been used in this work [31]. This
MSP-1 hybrid antigen also incorporates the conserved Block 1
region of MSP-1 which improves the immunogenicity of the
construct by inclusion of cognate T-cell help, since this region has
been shown to contain human and mouse T-cell epitopes [32,33].
MSP-119 is the C-terminal part of MSP-1, also known as MSP-1
Block 17 and is a highly conserved protein domain, rich in cysteine
residues and comprised of two EGF-like motifs [34–36]. Antibod-
ies that bind to certain epitopes of MSP-119 can inhibit invasion of
red blood cells by the merozoite stage of the parasite, through
inhibition of the proteolytic processing of MSP-1 [37–39].
Antibodies to MSP-119 purified from hyperimmune human serum
can inhibit parasite invasion in vitro [40]. In several seroepidemi-
ological studies, naturally exposed individuals with antibodies to
MSP-119 have shown reduced incidence of clinical malaria
[2,27,41,42].
Previous human clinical studies using MSP-119 derived vaccine
antigens have shown low immunogenicity in humans [43] and
most subsequent trials have utilized a larger C-terminal fragment,
MSP-142 that exhibits greater immunogenicity [44]. The region of
MSP-1 used in this study included MSP119, plus 35 C-terminal
residues of Block 16 present immediately upstream of MSP-119,
which contains human T-cell epitopes and has been shown to be
responsible for strong dimerization of P. vivax C-terminal MSP-1
constructs [45]. We hypothesized that inclusion of this upstream
Block 16 sequence would improve the immunogenicity of the
construct, as an MSP-119 vaccine construct expressed in
baculovirus containing the majority of this Block 16 sequence,
plus the N-terminal Block 1 region, showed superior pre-clinical
immunogenicity compared to MSP-119 alone [46].
In this study we have investigated the use of Tetrahymena
thermophila as an expression system for Plasmodium antigens by
expressing and purifying a synthetic vaccine antigen, MSP-1-
BBM, comprised of the conserved MSP-1 Block 1 region, the
multi-allelic MSP-1 Block 2 hybrid sequence, the dimerization
region of Block 16, and Block 17 of MSP-1. The aim is to develop
an MSP-1 based vaccine targeting both conserved and polymor-
phic regions of this major merozoite antigen, which can elicit
antibodies that are strain-transcending and functionally effective
against the malaria parasite. We present the results of immuno-
genicity testing in mice of this purified soluble vaccine antigen
from T. thermophila.
Materials and Methods
Ethics Statement
All in vivo experiments were carried out in accordance with the
Animals (Scientific Procedures) Act 1986 and conformed to the
Recommendations from the Declaration of Helsinki and the
Guiding Principles in the Care and Use of Animals. The
University of Edinburgh Ethical Review Committee approved
the project license on 3rd July 2006, reference number PL 13-06,
under which all mouse experimentation was performed. Mice
were humanely killed by Schedule 1 methods, in accordance with
licensing requirements. Group sizes were assessed prior to
experimentation to limit animal numbers while maintaining
sufficient statistical power.
Design and Cloning of MSP-1-BBM
The synthetic MSP-1-BBM antigen was designed as a four-
component construct encoding the MSP-1 hybrid sequence
composed of MSP-1 Block 1 and synthetic sequences covering
all three MSP-1 Block 2 serotypes [31], fused to residues 1572–
1702 of 3D7 strain MSP-1 (PlasmoDB.org ref. PFI1475W). The
signal sequence from MSP-1 was added to promote secretion of
the antigen [18]. The resulting sequence was codon optimized for
expression in Tetrahymena thermophila and synthesized by GeneArt
AG, Regensburg, Germany. All potential N-glycosylation sites
were removed by converting appropriate asparagine residues to
glutamine. To facilitate cloning of the open reading frame
encoding the antigen, an EcoRV restriction site was inserted
directly downstream of the start methionine within the MSP-1
signal sequence and a BglII site was inserted downstream of the
stop codon.
The MSP-1-BBM coding sequence was cloned by restriction/
ligation at the BglII and EcoRV sites into the expression cassette of
the pDL325 donor plasmid [18] and amplified in E. coli DH10B
cells (Invitrogen GmbH, Karlsruhe, Germany) under kanamycin
selection. The final expression plasmid p22X-MSP-1-BBM was
generated by the transfer of the expression cassette into the
integrative acceptor plasmid p22X by Cre/Lox recombination
[18,47].
The p22X plasmid is similar to pKOIX [18], but the DHFR-
TS integration sites were replaced by two 1.5 kb regions of a
protease gene locus (NCBI Genbank Accession XM_001027342).
The resulting vector is ,7.5 kb in size and contains a loxP site for
Cre-mediated integration of the expression cassette downstream of
the neo2 selection cassette [18,48]. Further details of the constructs
are available from the authors.
Ciliate Strains, Cultivation and Transformation
T. thermophila inbred strains B1868/4 and B2068/1 were used as
transformation hosts. Conjugating cells were transformed via
biolistic bombardment using standard protocols [49,50]. After-
wards, individual transformants were further cultivated at 30uC
without agitation, in 1.5 mL SPP-medium supplemented with
increasing concentrations of the antibiotic paromomycin (from
100 mg mL21 to 1000 mg mL21) for several weeks to support the
allelic assortment process. Small-scale cultivation was performed
in 1.5–10 mL SPP medium at 30uC and 80 rpm in a Multitron AJ
incubation shaker (Infors AG, Bottmingen, Switzerland).
Malaria Vaccine Expressed in T. thermophila
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SDS-PAGE and Western Blots
Whole-cell lysates and cell-free culture supernatant of recom-
binant T. thermophila induced with cadmium chloride (5 mg mL21
for 6–24 hours) were screened for MSP-1-BBM expression by
SDS-PAGE and Western blotting using standard methods [51].
Monoclonal antibodies 12.2 and 12.8, which recognize MSP-1
Block 2 and MSP-119 respectively, were kindly provided by Dr.
Jana McBride and used as primary antibodies [52]. Equal volumes
of serum from all mice immunized with MSP-1-BBM were mixed
to produce a pool. MSP-1 Block 2 hybrid protein [31] and
MSP119-GST fusion protein [53] were resolved by SDS-PAGE
and blotted onto nitrocellulose membrane, then probed with a
1:1000 dilution of pooled immune serum followed by anti-mouse
IR-Dye680 conjugated secondary antibody (Licor Biosciences
Ltd., Cambridge, UK). All Western blots were visualized using a
Licor Odyssey scanner.
Isocitrate Dehydrogenase (ICDH) Assay
Isocitrate dehydrogenase was selected as marker for cell damage
in T. thermophila cultures. The assay was performed spectropho-
tometrically according to the manufacturer’s recommended
protocol (Biochemika, Boehringer Mannheim GmbH, Germany).
Fermentation of Recombinant T. thermophila and Cell
Harvesting
Batch fermentation of T. thermophila was conducted in a Biostat
UD 50 fermentor (Sartorius, Goettingen, Germany) at 50-liter
scale. The fermentor was inoculated with 246103 cells mL21 and
cells were grown in SPP-based medium supplemented with 2.5 mg
mL21 E-64 (Peptanova GmbH, Sandhausen, Germany). The
temperature was maintained at 30uC and pO2 was controlled at
20% of the air saturation level by stirrer speed (150–250 rpm) and
air flow (10–35 L min21). The pH value was not regulated, with
an initial pH of 7.0.
MSP-1-BBM expression was induced by adding 5 mg mL21
cadmium chloride to the culture after 17 h of growth (cell density
of 0.256106 cells mL21). 40 h after inoculation (cell density:
1.76106 cells mL21), the culture broth was harvested cell-free by
filtration with a hollow fiber module (PES, 1 mm lumen, 3200 cm2
area, 0.5 mm cut off; Spectrum Laboratories Inc., USA),
producing 47 L of supernatant from 50 L culture. The filtrate
was concentrated to 2 liters using Sartocon Slice cassettes
(Sartorius, 10 kDa cut off) and concentrate was washed with
10 mM Phosphate buffer (pH 7.0) at the end of the concentration.
Finally, 536.4 g ammonium sulfate were added to 2 liters of
concentrate and incubated for 20 minutes on ice. Precipitated
protein was collected by centrifugation (60006G, 4uC). Superna-
tants were discarded and the protein pellet was frozen immediately
at 280uC.
Purification of MSP-1-BBM
Two antibody affinity columns were prepared by coupling
approximately 5 mg of either mAb 12.2 or mAb 12.8, which
recognize MSP-1 Block 2 and MSP-119 respectively, to 5 mL Hi-
Trap NHS-ester columns (GE Healthcare, UK) according to the
manufacturer’s recommended protocol.
Ammonium sulfate precipitates from culture supernatants of T.
thermophila expressing MSP-1-BBM were resuspended in Tris-
buffered saline (25 mM Tris, pH 8.0, 100 mM NaCl). This
solution was heated to 70uC for 20 minutes, cooled on ice for
20 minutes and finally centrifuged at 50006G for 30 minutes. The
feedstock was filtered using a 0.22 mM bottle-top filter (Pall
Corporation, UK) then loaded onto the 5 mL 12.8 mAb affinity
column and afterwards washed extensively with 25 mM Tris,
pH 8.0, 100 mM NaCl. Bound proteins were eluted with 0.1 M
Glycine, pH 2.7 into 1 M Tris, pH 9.0 neutralization buffer. The
eluate was loaded onto the 12.2 mAb column, washed extensively
with 25 mM Tris, pH 8.0, 100 mM NaCl and eluted with 0.1 M
Glycine pH 2.7 into a 1 M Tris pH 9.0 neutralization buffer.
Immunization of Mice
A group of five outbred female MF1 mice were immunized
subcutaneously on days 0, 14 and 28 with 100 mL volumes
containing 20 mg BBM protein formulated with CoVaccineHT
(Protherics Medicines Development Limited, A BTG International
Group Company, London, UK). The animals were exsanguinated
on day 40 and serum prepared from each. Naı¨ve mice from the
same breeding stock were used to provide serum for negative
control samples.
Antigens and Antibody Titer Determination by ELISA
Sera from MSP-1-BBM immunized animals were tested by
previously described ELISA for recognition of the MSP-1 Block 2
hybrid protein, MSP-1 Block 2 GST fusion proteins from all three
Block 2 serotypes, and MSP-119 GST fusion protein [31,53,54].
Negative control wells in ELISA were either coating buffer alone
for the MSP-1 hybrid, or GST-coated wells for GST fusion
proteins. All sera were tested across a range of tripling dilutions
(1:100 to 1:218,700) against each antigen in duplicate wells, with a
standard pool of Block 2- or MSP-119- positive sera also tested on
each plate, and across the same dilution range. Midpoint EC50
ELISA titers (arbitrary units) were calculated by interpolation from
the fitted standard curve on each plate using polynomial logistic
regression.
Indirect Immunofluorescence Assays (IFA)
Serum samples from mice immunized with MSP-1-BBM were
analyzed by IFA for parasite reactivity with the 3D7, MAD20 and
RO33 isolates of P. falciparum by methods previously described
[46,54]. Endpoint titers were calculated as the highest dilution at
which clear antibody reactivity with schizont stage parasites could
be observed under FITC fluorescence. IFA results were scored
independently by two experienced microscopists.
ELISA with Biotinylated Peptides
A set of 133 biotinylated dodecapeptides covering all possible
linear epitopes contained within MSP-1 Block 2 hybrid sequence
were synthesized by Mimotopes Pyt. Ltd. (Clayton, Australia).
ELISA plates (Greiner Bio One, UK) were coated with 100 mL of
5 mg mL21 streptavidin (Sigma) and incubated at 37uC until dry.
Plates were stored in heat sealed foil pouches with 1 g silica gel at
room temperature until use. Reactivity of sera against the peptide
library was determined by ELISA. Streptavidin-coated plates were
washed in PBS-T (PBS, 0.05% TweenH 20) and blocked with
blocking buffer (1% ByCoA, Croda Healthcare, UK dissolved in
PBS) for 5 hours at room temperature. Peptide library plates were
prepared by addition of 300 ng peptide per well, in duplicate, and
plates were incubated overnight at 4uC. Sera were added to each
well (100 mL at 1:500 dilution) and incubated overnight at 4uC,
then washed with PBS-T. Dilutions of a species-specific HRP-
linked secondary antibody (Dako, UK), appropriate to the serum
being tested, were added to each well and plates were incubated at
room temperature for 3 hours. Plates were washed three times
with PBS-T and OPD substrate was added to each well. Reactions
were stopped by addition of 0.2 M sulfuric acid and absorbance
Malaria Vaccine Expressed in T. thermophila
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e87198
was read at 492 nm using a microplate absorbance reader
(Multiskan Ascent, Thermo Scientific, UK).
Background reactivity of serum antibodies with peptides was
calculated as mean of all values in lowest two quartiles and a
positive threshold for reactivity was set as background plus 4 times
the standard deviation of these values. Antibody reactivity was
categorized as high where the OD reading was greater than 1
above threshold, moderate if above threshold or negative when
below threshold.
Mass Spectrometry
Mass spectrometry services were provided by the BSRC Mass
Spectrometry and Proteomics Facility, University of St Andrews.
The purified MSP-1-BBM product was resolved on a 4–12% poly-
acrylamide gel and the predominant gel band, of molecular weight
of ,60 kDa was excised and cut into 1 mm cubes. These were
then subjected to in-gel digestion, using a ProGest Investigator in-
gel digestion robot (Digilab) using standard protocols [45,55,56].
Briefly the gel cubes were destained by washing with a 1:1 mixture
of 30 mM potassium ferricyanide and 100 mM sodium thiosul-
phate and subjected to reduction and alkylation before digestion
with trypsin at 37uC. The peptides were extracted with 10%
formic acid and concentrated down using a SpeedVac (Thermo-
Savant).
The peptides were then separated on an Acclaim PepMap 100
C18 trap and an Acclaim PepMap RSLC C18 column (Thermo-
Fisher Scientific), using a nanoLC Ultra 2D plus loading pump
and nanoLC as-2 autosampler (Eskigent). The peptides were
eluted with a gradient of increasing acetonitrile, containing 0.1%
formic acid (5–40% acetonitrile in 5 min, 40–95% in a further
1 min, followed by 95% acetonitrile to clean the column, before
reequilibration to 5% acetonitrile). The eluent was sprayed into a
TripleTOF 5600 electrospray tandem mass spectrometer (AB-
Sciex) and analysed in Information Dependent Acquisition (IDA)
mode, performing 250 msec of MS followed by 100 msec MSMS
analyses on the 20 most intense peaks seen by MS. The MS/MS
data file generated was analysed using the Mascot algorithm
(Matrix Science) against a modified version of the NCBInr
database Aug 2013 incorporating the synthetic sequence of the
MSP-1-BBM protein. Searches were performed with no species
restriction, trypsin as the cleavage enzyme, carbamidomethyl as a
fixed modification of cysteines and methionine oxidation and
deamidation of glutamines and asparagines as a variable
modifications.
Results
Construction of the MSP-1-BBM Synthetic Gene and
Generation of Recombinant T. thermophila
A synthetic vaccine construct was synthesized that comprised
sequences from both conserved and polymorphic regions of MSP-
1: MSP-1 Blocks 1, 2, 16 and 17. The Block 1 sequence and Block
2 synthetic hybrid sequence used was identical to that previously
described for the MSP-1 hybrid antigen [18,31]. To this, the
highly conserved MSP-119 sequence without its GPI anchor
sequence was added C-terminally, in addition to an upstream 35
amino acid region from Block 16. The Block 16 sequence is
thought to be important in dimerization of MSP-1 when it is in the
MSP-142 form prior to secondary proteolytic processing [45,57].
The MSP-1 signal peptide (residues 1–19) sequence was added to
enable secretion of the protein into the culture supernatant
[18,31]. The resulting construct, MSP-1-BBM (MSP-1 Block 1,
Block 2, MSP-119), is 498 amino acids in size and is schematically
represented in Figure 1A.
The MSP 1-BBM DNA sequence was codon-optimized for the
host’s native codon usage frequency. During gene synthesis,
putative N-glycosylation sites encoded at MSP-1-BBM nucleotide
positions 538–540 and 715–717 were removed by substitution of
these asparagine residues with glutamine. The DNA sequence was
synthesized commercially and was successfully assembled with
cadmium inducible MTT1 promoter and the BTU2 terminator
[53,57] to create the final MSP-1-BBM expression cassette. The
expression cassette was transferred to the integrative acceptor
vector p22X that directed the transgene into the macronuclear
genome of T. thermophila by homologous recombination and
enabled selection of transformants by paromomycin.
Transformants were screened for expression and secretion of
MSP-1-BBM in the presence and absence of the inducer cadmium
chloride by SDS-PAGE and Western blot (data not shown). MSP-
1-BBM protein was detected in cadmium-induced cultures and a
single transformant with the highest secretion activity was selected
for all further work. An isocitrate dehydrogenase (ICDH) assay
indicated that MSP-1-BBM was present without the release of
elevated levels of the cytoplasmic enzyme ICDH, confirming that
extracellular MSP-1-BBM was not released upon cytolysis but
instead derived from protein export (data not shown).
Expression and Purification of MSP-1-BBM in T.
thermophila
The selected MSP-1-BBM T. thermophila cells were successfully
cultured in a 50 L stirred cell bioreactor and expression was
induced by addition of cadmium chloride. At the end of the batch
fermentation run, culture broth was harvested and concentrated
by precipitation with ammonium sulfate, yielding a wet pellet
weight of 313 g. As MSP 1-BBM is a thermostable protein, the
resuspended ammonium sulfate precipitate was heated to 70uC for
20 minutes, then centrifuged to remove contaminating denatured
proteins. MSP 1-BBM protein was then purified from the
supernatant of the heat-treated sample by affinity chromatogra-
phy, using two different affinity columns. The first mAb affinity
column (mAb 12.8) bound the C-terminal MSP-119 portion of the
protein. The eluate was loaded onto a second column coupled
with mAb 12.2 to bind proteins containing the N-terminal Block 2
domain of MSP-1. The purified protein was analyzed on
Coomassie stained SDS-PAGE gels and by Western blotting with
mAb 12.2 (Figure 2, panels A and B). A dominant band of
approximately 60 kDa was seen, corresponding to full-length
recombinant MSP-1-BBM (calculated molecular weight:
48.3 kDa). A number of minor bands of lower molecular weight
were present on the SDS-PAGE gel but not on the Western blot.
In Western blot analysis the 12.2 mAb reacted specifically with a
major band of approximately 60 kDa and with two minor bands
of approximately 114 and 120 kDa. The final yield of MSP-1-
BBM protein was determined by Bradford assay to be 0.5 mg.
The dominant ,60 kDa gel band was excised from a silver
stained SDS-PAGE gel and analyzed by electrospray tandem mass
spectrometry. Database searching of identified peptide sequences
against a custom NCBI database, which included the synthetic
MSP-1-BBM sequence, confirmed the identity of the excised
protein as MSP-1-BBM.
Immunogenicity Testing of Purified MSP-1-BBM
The immunogenicity of the MSP-1-BBM protein was tested by
immunizing mice subcutaneously on days 0, 14 and 28, then
generating sera from blood obtained by exsanguination on day 40.
Sera from immunized mice and control sera from naı¨ve mice were
tested by ELISA against MSP-1 Block 2 hybrid protein, MSP-1
Block 2-GST fusion proteins from all three Block 2 serotypes and
Malaria Vaccine Expressed in T. thermophila
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MSP-119-GST fusion protein (Figure 3). Sera from all five MSP-1-
BBM immunized mice reacted strongly with both the MSP-1
hybrid protein (geometric mean 376 AU, range 203 AU to
496 AU), K1-type Block 2 protein (geometric mean 371 AU,
range 139 Au to 847 AU), MAD20-type Block2 protein (geomet-
ric mean 144 AU, range 2 AU to 544 AU), RO33-type Block 2
protein (geometric mean 144 AU, range 2 AU to 3651 AU) and
MSP-119-GST fusion protein (geometric mean 5112 AU, range
1148 AU to 11736 AU) but did not react with GST alone. Sera
from naı¨ve mice gave no increased response above background
against any of the three antigens tested (data not shown).
Immunofluorescence and Western Blotting
Sera were tested by immunofluorescence assay (IFA) for
reactivity against P. falciparum blood stage parasites from three
strains representative of each of the three MSP-1 Block 2
serotypes; 3D7, MAD20 and RO33 (Figure 4). High antibody
titers were observed for all mice against each parasite strain. Sera
reacted against parasites from ring, trophozoite and schizont
stages, with strongest reactivity against the schizont stages where
the antibody localized to the surface of the individual merozoites
(Figure 4A). IFA endpoint titers were similar for all three strains of
parasite (3D7 parasite strain geometric mean titer 4222, range
800–25,600; MAD20 strain geometric mean titer 6400, range
1600–25,600; RO33 strain geometric mean 3840, range 1600–
6400) (Figure 4B). Differences between IFA titers were not
statistically significant (Kruskal-Wallis test, p = 0.667).
To confirm the presence of both MSP-1 Block 1/Block 2
sequences and the MSP-119 component within the MSP-1-BBM
immunogen, a pool of serum from all MSP-1-BBM immunized
mice was tested by Western blot against both the recombinant
MSP-1 Block 2 hybrid protein [18,19,31,58] and a MSP119-GST
fusion protein [18,53,59]. The pooled serum reacted strongly with
both recombinant proteins, confirming that antibodies were
elicited to both the C-terminal MSP-119 region, and to the N-
terminal Block1/2 part of MSP-1 (Figure 4C).
Figure 1. Schematic diagram of the MSP-1-BBM construct which encodes the N-terminal MSP-1 Block 1 region, the K1 Block 2
synthetic sequence, the RO33 Block 2 sequence, the MAD20 Block 2 synthetic sequence [31] and a C-terminal fragment encoding
residues 1571 to 1702 of MSP-1 precursor protein of P. falciparum. The Block 2 region is arranged similar to natural alleles. Synthetic Block 2
repeat sequences of the K1 and MAD20 serotypes are indicated by vertical and diagonal hatched markings, respectively.
doi:10.1371/journal.pone.0087198.g001
Figure 2. Analysis of purified MSP-1-BBM protein by SDS-PAGE
and Western blotting. A. Coomassie-stained gel of purified MSP-1-
BBM protein produced in T. thermophila. Lane 1. Molecular weight
markers. Lane 2. 0.5 mg purified MSP-1-BBM protein. B. Western blot of
MSP-1-BBM protein and MSP-1 hybrid probed with with mAb 12.2,
(specific for repeat sequences present in the K1 serotype of MSP-1 Block
2). Lane 1. Molecular weight markers. Lane 2. 0.5 mg of Tetrahymena-
derived MSP-1-BBM protein. Lane 3. Negative control. Lane 4. 0.5 mg
MSP-1 Block 2 hybrid protein [30] (positive control).
doi:10.1371/journal.pone.0087198.g002
Figure 3. Immunogenicity in mice of recombinant MSP-1-BBM
protein from T. thermophila [49]. A group of five MF1 mice were
immunized s.c. three times, at 2 week intervals with MSP-1-BBM protein
formulated in CoVaccine HT as described. Twelve days after the last
immunization (d40), serum samples from each animal were tested by
ELISA for antibody responses against the MSP-1 Block 2 hybrid protein
[31] K1-type Block 2 protein [54], MAD20-type Block 2 protein [54],
RO33-type Block 2 protein [54] and MSP-119 protein [53]. Titers were
calculated as outlined in materials and methods and expressed as
arbitrary units (AU). Data is shown on a natural logarithmic scale as
dotplots of serum reactivity for individual animals with the median level
of Ab reactivity indicated by the solid horizontal line.
doi:10.1371/journal.pone.0087198.g003
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Figure 4. Indirect immunofluorescence assay (IFA) of sera fromMSP-1-BBM immunized mice against three strains of P. falciparum. A.
Representative micrograph of IFA assay with sera from MSP-1-BBM immunized mice. DAPI staining of parasite nuclei is shown in blue and
fluorescence from the FITC-conjugated secondary antibody is shown in green. B. IFA titers of sera from mice immunized with MSP-1-BBM protein.
Sera were tested by IFA against the 3D7 (K1 serotype), MAD20 and RO33 strains of P. falciparum, as described in materials and methods. IFA endpoint
data is shown on a log10 scale on the Y axis. Each symbol represents the serum reactivity for an individual animal, with the geometric mean of Ab
Malaria Vaccine Expressed in T. thermophila
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Epitope Mapping by ELISA
To assess the epitope and serotype specificity of antibody
responses against the Block 2 region of MSP-1, sera were tested by
ELISA for reactivity with a panel of peptides containing all of the
linear epitopes from the three serotypes of Block 2 (Figure 5).
Antibody reactivity was observed against peptides containing
epitopes from all three Block 2 serotypes, but greater reactivity was
directed against peptides derived from the K1 Block 2 serotype
than the MAD20 serotype or RO33 serotype (Mann-Whitney
tests, p = 0.027 and p = 0.008 respectively).
Discussion
In this study we have successfully demonstrated recombinant
production of a malaria vaccine candidate antigen using the ciliate
protozoan T. thermophila. This expression platform has previously
been successfully used in a number of applications to express and
secrete heterologous proteins of therapeutic interest, and boasts a
number of favorable characteristics such as scalable growth to high
cell densities, eukaryotic protein folding, ability to target protein
for secretion and low biological hazard [18,19,58,60,61]. Howev-
er, the production of Plasmodium proteins in Tetrahymena as potential
vaccines has additional advantages, since Tetrahymena and Plasmo-
dium are closely related and share some characteristics important
for protein expression [17,18,59]. In particular, the prevalence of
AT-rich genes and highly repetitive sequence content of P.
falciparum can prove technically problematic for heterologous
expression in other expression systems [60–63]. Previous studies
have demonstrated that T. thermophila is able to express Plasmodium
proteins [17,18,58], but we are currently unaware of any reports of
the production of soluble malaria antigens using the T. thermophila
expression host.
Whereas P. falciparum makes little or no use of post-translation-
ally added N-linked glycans [62–64], T. thermophila extracellular
proteins can be modified with a high-mannose N-glycosylation
pattern [31,58,65,66]. All potential N-glycosylation sites were
removed from the synthetic gene to prevent inappropriate N-
glycosylation of MSP-1-BBM, which can have deleterious effects
on the magnitude and specificity of immune responses generated
to immunogens [34–36,64]. We assume that these modifications
had no deleterious effect on the conformation of MSP-1-BBM
because a strong antibody response against native parasite antigens
was elicited by immunization with the purified construct.
We successfully achieved secretion of the MSP-1-BBM protein
into the culture medium, as demonstrated by the presence of the
protein in the absence of elevated levels of the cytoplasmic protein
isocitrate dehydrogenase. This indicates that the MSP-1 signal
peptide was processed by a T. thermophila specific endopeptidase,
resulting in the release of the mature MSP-1-BBM antigen. While
the synthetic Block 2 domain is an intrinsically unstructured
protein domain, due to its unusual amino acid content [31,65–67],
MSP-119 contains two cysteine-rich EGF-like motifs [34–36,58],
whose conformational integrity is required to elicit invasion
inhibitory antibodies [57,67]. The targeting of MSP-1-BBM via
the secretory pathway ensured passage through the ER and Golgi
apparatus giving optimal likelihood for correct folding and
disulfide bond formation.
To produce MSP-1-BBM protein for immunogenicity testing, a
selected stable expression strain was cultivated in a batch
fermentation process at 50-liter scale. High cell densities of
,1.76106 cells mL21 were reached in a standard bioreactor
(Biostat UD 50 fermentor, Sartorius, Goettingen, Germany)
[58,68,69]. The cadmium-inducible MTT1 promoter regulated
recombinant antigen expression [57,68,70], so that timing of
MSP-1-BBM expression could be modified to start in the early
logarithmic phase of the cell culture. Western blot analysis
revealed expression of extracellular MSP-1-BBM after cadmium
addition and the soluble protein reacted with antibodies specific
for either the synthetic MSP-1 Block 2 sequence (Figure 2B) or the
MSP-119 domain (data not shown).
Following trials of a number of biochemical purification
techniques, protein purification was achieved using heat treatment
followed by a simple two-step monoclonal-antibody affinity
chromatography purification protocol. In the first step, mAb
12.8 that recognizes MSP-119 was used [31,68,69]. In the second
step, mAb 12.2 that recognizes an MSP-1 Block 2 epitope was
used to further purify MSP-1-BBM. The 12.8 mAb binds to a
highly conformational epitope [68,70–72], therefore we expect
that this step would purify only correctly folded protein. Use of a
second affinity column (mAb 12.2) favored the purification of full-
length protein, as both the Block 2 and Block 17 regions were
selected for during purification. A heat step had previously been
shown to be effective for the purification of the MSP-1 hybrid
antigen [31,60], in addition to the MSP-2 and MSP-3 proteins
[34,71,72]. These proteins are resistant to heat-induced protein
aggregation, due to the intrinsically unstructured nature of these
predominantly hydrophilic proteins. It was surprising to observe
that the MSP-1-BBM protein also exhibited heat stability, despite
it containing a substantial proportion of hydrophobic residues and
including a highly conformationally defined region (MSP-119)
comprised of two EGF-like motifs [31,60]. However, these motifs
are highly stabilized by the presence of six disulphide bridges
[34,73] which may provide sufficient structural stability to prevent
denaturation and aggregation of this protein moiety. The
thermostability of an antigen not only facilitates purification but
also is advantageous in terms of malaria vaccine development by
making a vaccine cold chain unnecessary [31,74].
After the heat step and affinity purification, 0.5 mg of full-length
MSP-1-BBM was obtained. Currently, no extensive optimization
of the production process has been carried out. Further gains in
production efficiency can be made through clone screening or by
optimization of harvesting and purification protocols, which would
have been facilitated by the use of affinity-tags or fusions to
enzymes such as glutathione-S-transferase (GST) [65,73]. Since
the main object of this project was to express a vaccine antigen, we
avoided the use of heterologous tags or fusions that may have
detrimentally influenced the immunogenicity or antigenicity of the
malaria vaccine antigen, as has been observed before [31,74]. We
anticipate that this further work could achieve greater yields of this
artificial and intrinsically unstructured antigen.
Purified MSP-1-BBM protein resolved as a major band in SDS-
PAGE corresponding to a molecular weight of approximately
60 kDa, whereas the predicted molecular weight from primary
sequence was 48.3 kDa. This slow migration was anticipated since
the MSP-1 Block 2 hybrid component has previously been shown
to exhibit slower electrophoretic mobility, as this predominantly
hydrophilic amino acid containing region of MSP-1-BBM binds
SDS weakly. As proteins with intrinsically unstructured regions
reactivity against each parasite strain indicated by the solid line. C. Western blot of MSP-1 Block 2 hybrid and MSP119 proteins probed with pooled
serum from mice immunized with MSP-1-BBM protein. Lane 1: Molecular weight markers, Lane 2: MSP-1 block 2 hybrid protein, Lane 3: MSP119-GST
fusion protein.
doi:10.1371/journal.pone.0087198.g004
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often have slow electrophoretic mobility [31], we confirmed the
identity of the 60 kDa band as MSP-1-BBM by tandem mass
spectrometry (see Materials and Methods). Some minor bands of
10–45 kDa were observed, and may indicate slight contamination
with host cell proteins or the presence of degradation products,
which were not detected by the 12.2 mAb, which detects an N-
Figure 5. Epitope mapping of sera from MSP-1-BBM immunized mice by recognition of peptide epitopes within the MSP-1 Block 2
region of the MSP-1-BBM construct. A series of 133 N-terminally biotinylated dodecapeptides, representing the sequence diversity of all three
Block 2 serotypes were used in ELISA to map the antibody specificities present in the sera of immunized animals. Reactivity with individual peptides is
shown as shaded boxes, with the depth of shading of each box representing the strength of reactivity of a 1:500 dilution of sera with each peptide.
The sequences and Block 2 serotype (K1, MAD20 and RO33) of each peptide are indicated down the right hand side of the diagram.
doi:10.1371/journal.pone.0087198.g005
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terminal MSP-1 epitope in MSP-1-BBM. A minor band of
approximately 120 kDa was observed on Western blots, which is
likely to be a dimeric form of MSP-1-BBM, although it is unknown
whether the putative dimerization region of Block 16 that is
present in the MSP-1-BBM construct mediates this.
The MSP-1-BBM protein was immunogenic in mice when
formulated with CoVaccineHT, raising high titers of antibodies
against both the MSP-1 hybrid and MSP-119 components,
including responses against all three MSP-1 block 2 serotypes
(Figures 3 and 4C). This confirms that the resulting construct was
both immunogenic using an adjuvant potentially suitable for
human use and antigenically similar to the MSP-1 hybrid. The
resulting antibodies reacted very strongly with parasites of all three
serotypes tested as assessed by IFA (Figure 4A), providing evidence
that the recombinant protein is antigenically similar to native
parasite proteins. As shown in Figure 5, antibody responses were
demonstrated to react with a number of individual peptides
composed of epitopes from the three Block 2 serotypes. However,
there was greater recognition of peptides containing epitopes from
the K1 type Block 2 serotype than the MAD20 or RO33 Block 2
serotypes. Murine humoral responses are often more oligoclonal
than other species, and recent pre-clinical validation of the related
MSP-1 hybrid vaccine antigen showed that rabbits and monkeys
produced broader antibody responses to a larger number of
epitopes within the MSP-1 hybrid protein [31,49]. In addition,
peptide ELISA is intrinsically less sensitive than ELISA using
whole proteins, so weaker responses may have been undetected in
this peptide-based ELISA. It is clear from the results of
immunofluorescence assays that antibodies to all three MSP-1
Block 2 serotypes were produced by all immunized mice, which
indicates that the MSP-1-BBM antigen can elicit a broad, strain
transcending antibody response to multiple parasite serotypes.
Sera from immunized mice reacted with parasites from ring,
trophozoite and schizont parasite stages. The Block 1, 2 and 16
components would be expected to elicit antibodies that react with
parasite stages expressing full-length MSP-1 (i.e. schizonts) in IFA
compared with antibodies to MSP-119, which would react with all
blood stages. This is explained by the fact that protein regions
coded by blocks 1, 2 and 16 are shed along with the remainder of
the MSP-1 complex upon merozoite invasion, leaving only the
Block 17 (MSP-119) component on the cell surface. This is likely to
account for the much brighter appearance of parasites of the
schizont stage in IFA, where the antibodies to all MSP-1
components can bind parasites, compared to the more selective,
MSP-119 specific reactivity seen with trophozoites and rings. To
confirm the specificity of the antibodies raised by immunization
with MSP-1-BBM, we showed that the sera from immunized mice
reacted strongly with both the MSP-1 Block 2 hybrid protein and
MSP119-GST fusion protein in Western blot, confirming that
antibodies were successfully raised against both individual
components of the vaccine antigen.
This fusion protein was evaluated with the aim of further
development as a malaria blood-stage vaccine, but there are
internal proteolytic cleavage sites in the vaccine antigen, separat-
ing the MSP-119 component from the MSP-1 Block1/2 compo-
nent, which led to reduced overall yields of full-length MSP-1-
BBM. This would complicate reproducible production of the
protein under cGMP. Future work will involve the removal of
these proteolytically sensitive sites by genetic manipulation of the
gene, and improvement of fermentation conditions using protease
knockout T. thermophila strains.
Conclusion
This study has successfully demonstrated the expression and
purification of a promising malaria vaccine candidate antigen in
the Tetrahymena thermophila expression system. We examined the
immunological characteristics of MSP-1-BBM secreted from T.
thermophila cells in MF1 mice and demonstrated that antibodies
raised to the protein showed reactivity with MSP-1 protein
epitopes from multiple parasite serotypes. The vaccine antigen
proved immunogenic using an adjuvant suitable for use in humans
and elicited antibodies in mice that recognized native parasite
antigens from all three MSP-1 Block 2 serotypes. Altogether, this
study represents an important step towards the establishment of
the Tetrahymena expression system for malaria antigens that will
provide a valuable tool for researchers facing the challenges that
some malaria antigens can present in more conventional
expression systems.
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